Biotechnologia.pl
łączymy wszystkie strony biobiznesu

Biotechnologia

42th Congress of International Society of Oncology and BioMarkers "Oncology in the Biomarker Era: Biology - Diagnostics - Therapy"
Data rozpoczęcia:
2015-10-03
Data zakończenia:
2015-10-07
Organizator:
Society of Oncology and BioMarkers
Miejsce
Zakopane
Link do strony

IMPORTANT!

The 42nd ISOBM annual Congress "Oncology in the Biomarker Era: Biology – Diagnostics – Therapy" was granted 18 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

 

The 42nd Congress of the International Society of Oncology and Biomarkers will be held in Zakopane, Poland, 3-7 October 2015 under the patronage of the President of the Republic of Poland. ISOBM organises the congress in collaboration with the European Group on Tumor Markers, with support of Polish Oncological Society and Polonorum Societas Biologiae Cellulae and several other Polish and international societes.

The International Society of Oncology and Biomarkers (ISOBM) was founded in the early 1970s.
The society was originally known as the International Society of Oncodevelopmental Biology and Medicine” (ISOBM), as the main interest of the founding members was in proteins involved in embryonic development as tumour markers. In 2010, with growing interests of the Society members in cancer biomarkers, tumour biology and novel cancer therapies, the name of the Society was changed into the International Society of Oncology and Biomarkers (also known as ISOBM).

We have selected the theme of the 42th Congress to be ‘Oncology in the Biomarker Era: Biology  Diagnostics  Therapy’, to cover most important fields of cancer research and oncology, including numerous aspects of personalised management of cancer patients, and to provide a platform for scientists, doctors and laboratory medicine specialists to share their knowledge, experience and different points of view.

Biomarkers, being currently a hot topic in cancer research and oncology, hold out promise for improving the clinical outcomes of cancer patients. This challenging theme requires interdisciplinary and innovatory approaches to translate new findings into clinical practice.

The participants will have an opportunity to exchange ideas and expertise in an international forum, to engage in collaboration, to meet with colleagues from all over the world, and to attend lectures delivered by prominent leaders in the field of Cancer Research, Oncology and Biomarkers.

KEYNOTE LECTURES will be given by:

prof. Aaron Ciechanover, 2004 Nobel Prize winner

prof. Herbert Fritsche, world expert on tumour markers

prof. Phil Gold, carcinoembionic antigen discoverer

prof. Ulf-Håkan Stenman, known for his outstanding contributions to standardisation of diagnostic assays

The scientific programme will also include:

20 ORAL SESSIONS

2 ROUND TABLE DISCUSSIONS

POSTER SESSIONS throughout the congress

 

Accepted abstracts will be published in Tumor Biology IF=3,611), the official ISOBM journal.

ISOBM 2015 has applied for accreditation with the UEMS-EACCME®

Laboratory diagnosticians participating in the ISOBM 2015 Congress will earn 31 credits from the National Chamber of Laboratory Medicine.

 

The Sessions will cover the following topics:
 
1. Classical Tumour Markers Present and Future I
2. From Tumour Biology to Biomarker-Based Decisions 
3. European Group for Tumour Markers Session
4. Big Data for Biomarker Development
5. Circulating Cancer Cells
6. Molecular Therapeutics and Predictive Biomarkers
7. Immunotherapy and Immunological Markers for the Management of Cancer Patients
8. Biobanking/Horizon 2020
9. Interdisciplinary Challenges
10. Hormones in the Aetiopathogenesis of Cancer
11. Liquid Biopsy
12. Molecularly-Driven Therapies
13. Cancer Stem Cells
14. Cancer Risk and Cancer Screening
15. Epigenetic Profiling, Tumour-Derived Nucleic Acids 
16. Towards Molecular Oncology - IncoNet EaP Session
17. Anticancer Drugs - New Developments, New Strategies
18. Molecular Tracing of Metastatic/Residual Diseases
19. Classical Tumour Markers Present and Future II
20. Targeting Tumour Microenvironment

 

The Congress language is English.

Abstract Submission Deadline: July 31, 2015
Early Registration Reduced Payment Deadline: August 13, 2015
Registration and Payment Deadline: August 27, 2015

 

 

Newsletter